You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers.
Title consistently uses the evidence-based approach Evidence-based tables make documentation of care plan easy Interdisciplinary orientation – all aspects of patient care are covered Only book that involves experts from the entire range of cancer treatment in the fields of medical, surgical and radiation oncology Includes hot topics such as prevention and breast cancer Offers ground-breaking sections on the latest research and clinical applications in cancer survivorship Chapter on PET addresses imaging issues and how to get the best results Most comprehensive sections on the biology and epidemiology of cancer as compared to competitors
Taking into account the many developments in the field of breast cancer research since the first edition, this color atlas addresses breast oncology in broad terms, with contributions written by surgeons, oncologists, pathologists, radiologists, and other breast cancer experts from the US. Covers risk factors, epidemiology, and development of breast cancer; normal anatomy and development; prevention; breast imaging; surgery; breast biopsy processing; benign breast disorders; pathology; radiotherapy; the principles of systemic therapy; adjuvant systemic therapy; and locally advanced, locally recurrent, and metastatic breast cancer. Visuals play a significant role, with many color photographs, tables, charts, graphs, and figures. Annotation copyrighted by Book News, Inc., Portland, OR
This text reviews the latest ideas in tumor biology, explains the pharmacologic basis of the agents used, and discusses how they are applied in clinical practice. Part One presents an overview of the clinical importance of endocrine therapy, and describes the applications of the principal classes of drugs, including antiestrogens, aromatase inhibitors, progestins, and progesterone receptor antagonists. This section also discusses ovarian ablation. Part Two deals with the biological aspects of endocrine therapies, and relates current understanding of tumor biology and the pharmacologic basis of hormonal agents to their clinical applications. Among the topics covered are resistance and sensitivity to therapy. Part Three outlines future strategies, in particular the use of combination endocrine therapy, adjuvant growth factor therapy and the use of anti-invasive agents. This text is essential for oncologists and pharmacologists alike.
Technologies collectively called omics enable simultaneous measurement of an enormous number of biomolecules; for example, genomics investigates thousands of DNA sequences, and proteomics examines large numbers of proteins. Scientists are using these technologies to develop innovative tests to detect disease and to predict a patient's likelihood of responding to specific drugs. Following a recent case involving premature use of omics-based tests in cancer clinical trials at Duke University, the NCI requested that the IOM establish a committee to recommend ways to strengthen omics-based test development and evaluation. This report identifies best practices to enhance development, evaluation, and translation of omics-based tests while simultaneously reinforcing steps to ensure that these tests are appropriately assessed for scientific validity before they are used to guide patient treatment in clinical trials.
None
None